Physician profile
Heather Suzanne Brown
NPI 1134733611
$2,227.12
in general payments reported to CMS, 2019-2025
14 companies · $529 in 2025
The $529 reported for 2025 was more than what a typical Gerontology (Nurse Practitioner) provider received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $150 · 2022: $219 · 2023: $525 · 2024: $804 · 2025: $529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,533 · Education: $209 · Consulting Fee: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,533.42 |
| Education | $209.30 |
| Consulting Fee | $115.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $988.80 | 2023-2025 | Darzalex, Tecvayli, Carvykti |
| Janssen Scientific Affairs, LLC | $293.28 | 2023-2025 | Talvey, Tecvayli, Darzalex |
| E.R. Squibb & Sons, L.L.C. | $230.70 | 2022-2023 | Reblozyl |
| Glaxosmithkline, LLC. | $150.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $122.54 | 2023-2025 | Imfinzi |
| Seagen INC. | $114.75 | 2023 | Padcev |
| Legend Biotech USA INC. | $81.69 | 2025 | Carvykti |
| Astellas Pharma US INC | $71.00 | 2024 | |
| Karyopharm Therapeutics INC. | $66.70 | 2022 | |
| Celgene Corporation | $35.20 | 2024 | |
| Beone Medicines USA, INC. | $28.86 | 2025 | Brukinsa |
| Genzyme Corporation | $20.00 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.36 | 2022 | |
| Janssen Pharmaceuticals, INC | $8.24 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.